Hansson, Oskar;
Edelmayer, Rebecca M;
Boxer, Adam L;
Carrillo, Maria C;
Mielke, Michelle M;
Rabinovici, Gil D;
Salloway, Stephen;
... Teunissen, Charlotte E; + view all
(2022)
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.
Alzheimer's & Dementia
, 18
(12)
pp. 2669-2686.
10.1002/alz.12756.
Preview |
Text
Zetterberg_ Hansson - The Alzheimer s Association appropriate use recommendations for blood biomarkers.pdf Download (798kB) | Preview |
Abstract
Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs. We already now recommend use of BBMs as (pre-)screeners to identify individuals likely to have AD pathological changes for inclusion in trials evaluating disease-modifying therapies, provided the AD status is confirmed with positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. We also encourage studying longitudinal BBM changes in ongoing as well as future interventional trials. However, BBMs should not yet be used as primary endpoints in pivotal trials. Further, we recommend to cautiously start using BBMs in specialized memory clinics as part of the diagnostic work-up of patients with cognitive symptoms and the results should be confirmed whenever possible with CSF or PET. Additional data are needed before use of BBMs as stand-alone diagnostic AD markers, or before considering use in primary care.
| Type: | Article |
|---|---|
| Title: | The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/alz.12756 |
| Publisher version: | https://doi.org/10.1002/alz.12756 |
| Language: | English |
| Additional information: | © 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/). |
| Keywords: | Alzheimer's disease, appropriate use recommendations, blood-based biomarkers, diagnosis, prognosis |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10153549 |
Archive Staff Only
 |
View Item |
